Drug Type Antibody drug conjugate (ADC) |
Synonyms Claudin 18.2 ADC - Shandong Boan Biotechnology, BA1301, PR 301 + [1] |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), Tubulin inhibitors |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | Phase 2 | China | - | |
| Pancreatic Cancer | Phase 2 | China | - | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 11 Jan 2023 | |
| stomach adenocarcinoma | IND Approval | China | 30 Sep 2025 | |
| Gastrooesophageal junction cancer | Preclinical | United States | 22 Jan 2024 |






